within Pharmacolibrary.Drugs.ATC.J;

model J05AB18
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.9966666666666666,
    adminDuration  = 600,
    adminMass      = 0.8,
    adminCount     = 1,
    Vd             = 0.142,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Molnupiravir is an oral antiviral prodrug of the ribonucleoside analog N4-hydroxycytidine. It inhibits replication of SARS-CoV-2, the virus responsible for COVID-19. It is used for the treatment of mild to moderate COVID-19 in adults at risk of progressing to severe disease. It has received emergency use authorization in some regions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers (median age 25-52 years) after oral administration, single dose, fasting state.</p><h4>References</h4><ol><li><p>Saravolatz, LD, et al., &amp; Sharma, M (2023). Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> 76(1) 165–171. DOI:<a href=&quot;https://doi.org/10.1093/cid/ciac180&quot;>10.1093/cid/ciac180</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35245942/&quot;>https://pubmed.ncbi.nlm.nih.gov/35245942</a></p></li><li><p>Bhardwaj, M, et al., &amp; Nandi, U (2023). Impact of Disease States on the Oral Pharmacokinetics of EIDD-1931 (an Active Form of Molnupiravir) in Rats for Implication in the Dose Adjustment. <i>Molecular pharmaceutics</i> 20(9) 4597–4610. DOI:<a href=&quot;https://doi.org/10.1021/acs.molpharmaceut.3c00314&quot;>10.1021/acs.molpharmaceut.3c00314</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37527414/&quot;>https://pubmed.ncbi.nlm.nih.gov/37527414</a></p></li><li><p>Carlin, AF, et al., &amp; Hostetler, KY (2024). Oral pharmacokinetics and efficacy of oral phospholipid remdesivir nucleoside prodrugs against SARS-CoV-2 in mice. <i>Antimicrobial agents and chemotherapy</i> 68(10) e0103924–None. DOI:<a href=&quot;https://doi.org/10.1128/aac.01039-24&quot;>10.1128/aac.01039-24</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39240093/&quot;>https://pubmed.ncbi.nlm.nih.gov/39240093</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AB18;
